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SLC6A8 is such a gene (with 13 exons, a 635-aa coding
sequence, and no indication of highly recurring muta-
tions), and thus we predict that its incidence in “nonsyn-
dromic” MR will be in the range of 0.1%–0.3%. Indeed,
even for the ARX (X-linked Aristaless) gene, which has
a clear mutation hotspot that accounts for ∼6.6% of fam-
ilies with X-linked “nonsyndromic” MR, the incidence of
this ARX recurring mutation in cohorts of patients with
MR is much lower (∼0.15%) than that of FMR1 muta-
tions (Grønskov et al. 2004; Mandel and Chelly 2004).
I also suggest that, in reporting prevalence estimates
that are based on relatively small numbers of positive
cases, it would be useful to give conﬁdence intervals
(CIs). Thus, the observed prevalence, in the study by
Rosenberg et al. (2004), of 2.2% may indeed be an un-
derestimate, since some mutations may have beenmissed
and some variants of uncertain signiﬁcance at present
may prove pathogenic, or it may be an overestimate of
the true prevalence, since, for the reported data, the CI
for the prevalence of proven mutations is 1.0%–4.4%.
J. L. MANDEL
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Reply to Mandel
To the Editor:
On behalf of all the authors of our recent study (Rosen-
berg et al. 2004), we thank Dr. Mandel for his comments
(Mandel 2004 [in this issue]), to which we fully subscribe,
and we apologize for the misleading statement in our
article. Indeed, SLC6A8 mutations, although probably
more common than mutations in other known nonsyn-
dromic X-linked mental retardation (MRX) genes except
ARX, must be much less frequent than pathogenic CGG
expansions in the FMR1 gene. As pointed out by Mandel
(2004 [in this issue]), this is convincingly illustrated by
the relative paucity of ARX mutations in nonselected co-
horts of males with mental retardation (MR) (Grønskov
et al. 2004). Mandel’s second argument, which implies
that mutation rates in X-linked genes can be inferred from
their lengths and must be intrinsically much lower than
the rate of CGG expansions in FMR1, is less compelling
in view of the evidence for mutational hotspots in many
disease genes, including ARX and PQBP1, a recent ad-
dition to the growing list of genes involved in MRX (Kal-
scheuer et al. 2003). Therefore, the existence of another
common but hitherto-unknown cause of nonsyndromic
MR cannot be ruled out yet, even though ongoing large-
scale mutation screening in regions known to carry many
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mutations (Ropers et al. 2003) has so far failed to identify
such a gene.
Reliable estimation of the relative importance of
SLC6A8 and other MRX genes in the etiology of MR
will have to await systematic screening of large, unse-
lected cohorts of patients with MR. So far, comprehen-
sive studies of this kind have only been reported for a
few genes, including FMR1 and ARX.
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